Alberto Zambon

10.1k total citations · 2 hit papers
90 papers, 5.9k citations indexed

About

Alberto Zambon is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Alberto Zambon has authored 90 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Surgery, 48 papers in Endocrinology, Diabetes and Metabolism and 27 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Alberto Zambon's work include Lipoproteins and Cardiovascular Health (52 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (42 papers) and Lipid metabolism and disorders (21 papers). Alberto Zambon is often cited by papers focused on Lipoproteins and Cardiovascular Health (52 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (42 papers) and Lipid metabolism and disorders (21 papers). Alberto Zambon collaborates with scholars based in Italy, United States and United Kingdom. Alberto Zambon's co-authors include John E. Hokanson, John D. Brunzell, B. Greg Brown, John D. Brunzell, Bruce A. Griffin, Samir S. Deeb, Paolo Magni, Jean‐Pierre Després, Raúl D. Santos and Benoît J. Arsenault and has published in prestigious journals such as The Lancet, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Alberto Zambon

83 papers receiving 5.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity

2020 1.1k citations Robert Ross, Ian J. Neeland et al. Nature Reviews Endocrinology profile →
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement

2019 917 citations Ian J. Neeland, Robert Ross et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alberto Zambon Italy	33	2.3k	1.8k	1.5k	1.3k	1.2k	90	5.9k
Manuel Castro Cabezas Netherlands	37	1.6k 0.7×	999 0.6×	1.2k 0.8×	1.2k 0.9×	1.2k 1.1×	150	5.1k
Klaus G. Parhofer Germany	48	3.0k 1.3×	3.5k 2.0×	2.1k 1.4×	1.5k 1.2×	1.8k 1.5×	248	8.9k
Ingebjørg Seljeflot Norway	48	1.1k 0.5×	1.6k 0.9×	2.9k 2.0×	1.3k 1.0×	1.1k 0.9×	321	8.2k
Juan Pedro‐Botet Spain	39	1.8k 0.8×	2.2k 1.2×	936 0.6×	663 0.5×	664 0.6×	298	5.2k
Evangelos Liberopoulos Greece	42	2.2k 0.9×	2.3k 1.3×	1.1k 0.7×	603 0.5×	1.3k 1.1×	292	6.2k
Asterios Karagiannis Greece	43	2.6k 1.1×	1.8k 1.0×	1.6k 1.1×	866 0.7×	1.8k 1.5×	215	6.6k
Bruno Vergès France	47	4.1k 1.8×	2.1k 1.2×	1.2k 0.8×	910 0.7×	2.4k 2.0×	295	8.0k
Roberto Testa Italy	48	1.7k 0.7×	1.6k 0.9×	1.6k 1.1×	1.1k 0.9×	2.4k 2.1×	238	8.3k
Κωνσταντίνος Τζιόμαλος Greece	45	2.4k 1.0×	1.7k 0.9×	1.5k 1.0×	917 0.7×	2.3k 2.0×	308	7.7k
Anand Rohatgi United States	32	1.4k 0.6×	1.7k 1.0×	2.4k 1.6×	1.1k 0.8×	1.3k 1.1×	100	5.8k

Countries citing papers authored by Alberto Zambon

Since Specialization

Citations

This map shows the geographic impact of Alberto Zambon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Zambon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Zambon more than expected).

Fields of papers citing papers by Alberto Zambon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Zambon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Zambon. The network helps show where Alberto Zambon may publish in the future.

Co-authorship network of co-authors of Alberto Zambon

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Zambon. A scholar is included among the top collaborators of Alberto Zambon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Zambon. Alberto Zambon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Isla, Leopoldo Pérez de, Evangelos Liberopoulos, Melania Dovizio, et al.. (2024). Differential Adherence to Free and Single-Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real-World Analysis in Italy. Advances in Therapy. 41(8). 3407–3418. 3 indexed citations

Zambon, Alberto, et al.. (2023). Adherence to free and single-pill combination of rosuvastatin/ezetimibe: findings from a real-world analysis in italy. European Journal of Preventive Cardiology. 30(Supplement_1). 1 indexed citations

Masana, L., Alberto Zambon, Claus Peter Schmitt, et al.. (2023). Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients - Results from the efficacy phase of the APH-19 study. Atherosclerosis. 379. S23–S24. 3 indexed citations

Aguíar, Carlos, Nasreen Al-Sayed, М. В. Ежов, et al.. (2023). Non-HDL-cholesterol in dyslipidemia: Review of the state-of-the-art literature and outlook. Atherosclerosis. 383. 117312–117312. 77 indexed citations

Masana, L., Alberto Zambon, Claus Peter Schmitt, et al.. (2023). Lomitapide for the treatment of paediatric homozygous familial hypercholesterolaemia patients - Results from the efficacy phase of the APH-19 study. SHILAP Revista de lepidopterología. 54. S9–S9. 1 indexed citations

Adorni, Maria Pia, Francesca Zimetti, Nicoletta Ronda, et al.. (2022). HDL Cholesterol Efflux and Serum Cholesterol Loading Capacity Alterations Associate to Macrophage Cholesterol Accumulation in FH Patients with Achilles Tendon Xanthoma. International Journal of Molecular Sciences. 23(15). 8255–8255. 6 indexed citations

Cefalù, Angelo B., Laura D’Erasmo, Gabriella Iannuzzo, et al.. (2022). Efficacy and safety of lomitapide in familial chylomicronaemia syndrome. Atherosclerosis. 359. 13–19. 14 indexed citations

Puato, Massimo, Alberto Zambon, Elisabetta Faggin, et al.. (2021). Lipid Profile and Vascular Remodelling in Young Dyslipidemic Subjects Treated with Nutraceuticals Derived from Red Yeast Rice. Cardiovascular Therapeutics. 2021. 1–8. 4 indexed citations

Cicero, Arrigo F.G., Federica Fogacci, & Alberto Zambon. (2021). Red Yeast Rice for Hypercholesterolemia. Journal of the American College of Cardiology. 77(5). 620–628. 56 indexed citations

10.

Casula, Manuela, Marta Gazzotti, Marcello Arca, et al.. (2020). Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study. Journal of Internal Medicine. 290(1). 116–128. 25 indexed citations

11.

Ross, Robert, Ian J. Neeland, Shizuya Yamashita, et al.. (2020). Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nature Reviews Endocrinology. 16(3). 177–189. 1094 indexed citations breakdown →

12.

Malvandi, Amir Mohammad, et al.. (2020). Progress and prospects of biological approaches targeting PCSK9 for cholesterol-lowering, from molecular mechanism to clinical efficacy. Expert Opinion on Biological Therapy. 20(12). 1477–1489. 3 indexed citations

13.

Neeland, Ian J., Robert Ross, Jean‐Pierre Després, et al.. (2019). Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. The Lancet Diabetes & Endocrinology. 7(9). 715–725. 917 indexed citations breakdown →

14.

Cimminiello, Claudio, Alberto Zambon, & Hernan Polo Friz. (2016). Colesterolo e rischio cardiovascolare: pregi e limiti delle attuali terapie. Giornale italiano di cardiologia. 17(4). 6S–13. 8 indexed citations

15.

Zambon, Alberto. (2014). The new ACC/AHA guidelines on the treatment of dyslipidemia: cons. Internal and Emergency Medicine. 10(2). 119–122. 1 indexed citations

16.

Cagnin, Annachiara, et al.. (2013). LDL Density and Oxidation are Modulated by PON1 Promoter Genotype in Patients with Alzheimer's Disease. Journal of Alzheimer s Disease. 34(2). 377–385. 7 indexed citations

17.

Zambon, Alberto, et al.. (2008). [Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].. PubMed. 9(4 Suppl 1). 29S–39S. 9 indexed citations

18.

Staels, Bart, Michaël Maes, & Alberto Zambon. (2008). Fibrates and future PPARα agonists in the treatment of cardiovascular disease. Nature Clinical Practice Cardiovascular Medicine. 5(9). 542–553. 133 indexed citations

19.

Zambon, Alberto & Gaetano Crepaldi. (2003). The plurimetabolic syndrome: qualitative lipoprotein abnormalities and atherosclerosis. International Congress Series. 1253. 223–228.

20.

Zambon, Alberto, Samir S. Deeb, B. Greg Brown, John E. Hokanson, & John D. Brunzell. (2001). Common Hepatic Lipase Gene Promoter Variant Determines Clinical Response to Intensive Lipid-Lowering Treatment. Circulation. 103(6). 792–798. 97 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact